API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
BDSI intends to launch ELYXYB in the first quarter of 2022. Additionally, BDSI plans to conduct an ELYXYB pediatric study, which will have the potential to address the significant unmet needs of pediatric and adolescent patients suffering from migraine attacks.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioDelivery Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 09, 2021
Details:
ELYXYB is an oral solution of celecoxib, formulated using a self-micro emulsifying drug delivery system that improves solubility and bioavailability of the drug leading to better absorption.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioDelivery Sciences
Deal Size: $15.0 million Upfront Cash: $6.0 million
Deal Type: Acquisition August 04, 2021
Details:
Ethypharm has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. Celecoxib is developed by Dr Reddy's.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ethypharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 19, 2021
Details:
The collaboration is focused on advancing the clinical development of the lead product candidate PrimeC (ciprofloxacin and celecoxib), which is currently undergoing mid-stage clinical trials for treating Alzheimer's disease.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NeuroSense Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 22, 2024
Details:
Lonza will develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes, set to be integrated into the development program of PrimeC, a novel extended-release oral formulation of a unique fixed-dose combination of ciprofloxacin and celecoxib, by NeuroSense.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lonza Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 09, 2024
Details:
PrimeC is a novel extended-release oral formulation composed of a unique FDC of ciprofloxacin and celecoxib. It is under phase 2 clinical development for the treatment of amyotrophic lateral sclerosis (ALS).
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
IMC-2 (combination of valacyclovir and celecoxib) is being evaluated in phase 2 clinical trials as a potential treatment for managing the fatigue, sleep, attention, pain, autonomic function and anxiety associated with Long COVID.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
IMC-2 (combination of valacyclovir + celecoxib) is being evaluated in phase 2 clinical trials as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC illness, also known as post-acute sequelae of SARS-CoV-2 infection (PASC) or Long Covid.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
Elyxyb (celecoxib) is a nonsteroidal anti-inflammatory drug that acts as a cyclooxygenase-2 inhibitor. It is indicated for the acute treatment of migraine with or without aura in adults.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
PrimeC is a novel extended-release oral formulation composed of a unique FDC of ciprofloxacin and celecoxib. It is under phase 2 clinical development for the treatment of amyotrophic lateral sclerosis (ALS).
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
Elyxyb (celecoxib) is a nonsteroidal anti-inflammatory drug with analgesic, anti-inflammatory, and antipyretic properties. Celecoxib inhibits prostaglandin synthesis, primarily via inhibition of COX-2. It is being developed for migrane pain.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2023
Details:
PrimeC (ciprofloxacin and celecoxib) is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired RNA regulation to potentially inhibit the progression of ALS.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
PrimeC (ciprofloxacin and celecoxib) is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired RNA regulation to potentially inhibit the progression of ALS.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
NeuroSense terminated the offering as the company is fully funded beyond clinical phase 2b ALS results of PrimeC, a unique formulation of a fixed-dose combination drug comprising ciprofloxacin and celecoxib, for amyotrophic lateral sclerosis.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering October 02, 2023
Details:
The Company has initiated the 10-day termination process under the Sales Agreement and is focusing its attention on short-to-medium term operational priorities, including assessment of IMC-2 (fixed combination of valacyclovir and celecoxib) in Long-COVID.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: JonesTrading Institutional Services
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination September 18, 2023
Details:
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity and is being evaluated in combination with Paclitaxel in Phase 1 Study for the treatment of people with early-stage triple negative breast cancer.
Lead Product(s): Rintatolimod,Celecoxib,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
F14 (celecoxib) is a sustained-release formulation of the non-steroidal anti-inflammatory drug (NSAID), celecoxib, administered into the intra-articular space at the end of TKR surgery.
Lead Product(s): Celecoxib,Bupivacaine Hydrochloride,Paracetamol
Therapeutic Area: Neurology Product Name: F14 (mdc-CWM)
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
IMC-1 (famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. It is being investegated for the treatment of fibromyalgia.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
IMC-2 is a combination of valacyclovir, which inhibits viral DNA polymerase and celecoxib, which is COX-2 inhibitor, as a potential treatment for managing fatigue, sleep, attention, pain, autonomic function and anxiety associated with post-acute sequelae of COVID-19.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
The net proceeds will advance the clinical development of PrimeC (ciprofloxacin) for amyotrophic lateral sclerosis and for the clinical development potential investigational new drug applications for Alzheimer's disease, for Parkinson's disease and for other indications.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 22, 2023
Details:
Under the terms of the agreement, Biogen will evaluate the impact of PrimeC (ciprofloxacin) and celecoxib on neurofilament levels in the plasma of participants in PARADIGM, NeuroSense’s Phase 2b clinical trial for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 14, 2023
Details:
PrimeC (ciprofloxacin and celecoxib) is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired RNA regulation to potentially inhibit the progression of ALS.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
StabiliC is a combination consisting of ciprofloxacin and celecoxib which is currently being investigated in preclinical studies for the treament of parkinson's disease.
Lead Product(s): Celecoxib,Ciprofloxacin
Therapeutic Area: Neurology Product Name: StabiliC
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
IMC-1 (famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. It is being investegated for the treatment of fibromyalgia.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
NeuroSense & Massachusetts General Hospital will explore the neurotherapeutic effects of PrimeC, utilizing a novel in vitro model generated from post-mortem ALS brain tissue. PrimeC is a novel unique fixed-dose combination of ciprofloxacin and celecoxib.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Massachusetts General Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 27, 2023
Details:
Elyxyb (celecoxib) is a nonsteroidal anti-inflammatory drug with analgesic, anti-inflammatory, and antipyretic properties. Celecoxib inhibits prostaglandin synthesis, primarily via inhibition of COX-2. It is being developed for migrane pain.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
IMC-2 is a combination of valacyclovir, which inhibits viral DNA polymerase and celecoxib, which is COX-2 inhibitor, as a potential treatment for managing fatigue, sleep, attention, pain, autonomic function and anxiety associated with post-acute sequelae of COVID-19.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Through the acquisition, ELYXYB has the potential to further expand Scilex’s non-opioid portfolio in broader acute pain indications. ELYXYB is an oral solution of celecoxib, formulated using a self-micro emulsifying drug delivery system.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Scilex Holding Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 12, 2023
Details:
PrimeC (ciprofloxacin and celecoxib) is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired RNA regulation to potentially inhibit the progression of ALS.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
IMC-1 (Famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 has been granted fast track designation by the FDA.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
PrimeC is a novel formulation composed of unique doses of two FDA-approved drugs, Ciprofloxacin and Celecoxib, which aim to synergistically inhibit the progression of ALS by aiming to regulate microRNA synthesis, reduce neuroinflammation, and influence iron accumulation.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
PrimeC's (ciprofloxacin) upgraded formulation, which is a unique extended-release tablet, designed to maximize the synergism between the compounds, is now being evaluated in a Phase IIb clinical trial, PARADIGM, for the treatment of ALS.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 (famciclovir) and for working capital and general corporate purposes.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering September 22, 2022
Details:
PrimeC (ciprofloxacin) is a novel extended-release oral formulation composed of a unique fixed-dose combination of the two drugs, which are U.S. Food and Drug Administration (FDA)-approved. NeuroSense is currently evaluating PrimeC in PARADIGM, a Phase IIb clinical trial.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 (famciclovir) and for working capital and general corporate purposes.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 19, 2022
Details:
IMC-1 (famciclovir) was well-tolerated overall, with only 4.6% of patients dropping out due to adverse events, as compared with 8.1% of placebo treated patients. No adverse event category in the IMC-1 group exceeded a 4% rate with the exception of COVID-19 infection.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
Phase IIa clinical study of PrimeC's (ciprofloxacin) successfully met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biological markers.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
ELYXYB™ (celecoxib) oral solution is prescription nonsteroidal anti-inflammatory drug (NSAID) used for the acute treatment of migraine with or without aura in adult.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
Ampligen (rintatolimod) is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
Lead Product(s): Rintatolimod,Interferon Alfa-2B,Celecoxib
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roswell Park Comprehensive Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
IMC-2 (valacyclovir + celecoxib), to treat the symptoms associated with Long-COVID, including fatigue, pain, sleep disruption, anxiety, depression and cognitive function and overall health improvement.
Lead Product(s): Valacyclovir,Celecoxib
Therapeutic Area: Infections and Infectious Diseases Product Name: IMC-2
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC).
Lead Product(s): Rintatolimod,Interferon Alfa-2B,Celecoxib
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
The primary efficacy endpoint met and studied was summed pain intensity difference from 0 to 48 hours (SPID0-48). SEGLENTIS (celecoxib) had a significantly greater effect on SPID0-48 (least-squares mean: −139.1 than tramadol, celecoxib or placebo.
Lead Product(s): Celecoxib,Tramadol Hydrochloride
Therapeutic Area: Neurology Product Name: Seglentis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
Phase IIa clinical study which successfully met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biological markers indicating PrimeC (ciprofloxacin) biological activity.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
PrimeC is a novel formulation composed of unique doses of two FDA-approved drugs, Ciprofloxacin and Celecoxib, which aim to synergistically inhibit the progression of ALS.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Phase IIa study for PrimeC (Ciprofloxacin), successfully met safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biomarkers.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Analysis of gastric mucosa biopsies revealed a significant positive association between actively replicating gastric HSV-1 and multiple functional gastrointestinal disorders, with and without concomitant FM.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Alabama
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
PrimeC (ciprofloxacin), is a novel formulation consisting of unique doses of two FDA-approved drugs designed to work synergistically on several targets including regulating microRNA synthesis, affecting iron accumulation, and reducing neuroinflammation.
Lead Product(s): Ciprofloxacin,Celecoxib
Therapeutic Area: Neurology Product Name: PrimeC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. This dual mechanism antiviral therapy is designed to synergistically suppress herpes virus activation and replication.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
The data, from a small number of subjects, is extremely impressive for four out of six Ampligen plus pembrolizumab patients; three demonstrated disease stabilization and one showed a significant and dramatic rapid destruction of the tumor and metastasis.
Lead Product(s): Rintatolimod,Celecoxib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roswell Park Comprehensive Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022